Article

Diabetes coding requires sophistication

There are many issues when it comes to coding and providing reimbursement for the myriad effects diabetes has on the eye. New ICD-9-CM codes for diabetic retinopathy were added in 2006, and those new codes should be used rather than those from older manuals. Diabetic retinopathy is one of four ophthalmic conditions eligible for reporting under Medicare's Physician Quality Reporting Initiative. That program will provide a 1.5% payment bonus for meeting the reporting benchmarks.

Key Points

Also, diabetic retinopathy has been selected as one of the four ophthalmic conditions eligible for reporting under Medicare's Physician Quality Reporting Initiative. This is the "pay for performance" program that will provide a 1.5% payment bonus for meeting the reporting benchmarks.

Several principles of diagnostic coding are relevant for the diabetic population. Diagnoses should be chosen at the highest level of specificity. Also, multiple codes should be used when present. New ICD-9-CM codes for diabetic retinopathy were added in 2006, and these new codes should be used rather than those from the older manuals.

The importance and complexity of the encounter is diminished from the payers' perspective when nonspecific diagnostic codes are used and when relevant additional diagnostic codes are omitted.

Patients with any ophthalmic manifestation of diabetes mellitus will be coded ICD-9-CM 250.5, with a fifth digit added depending on the type of diabetes (type I versus type II), and whether or not the diabetes is under control. Typically, your encounter has added importance both when the diabetes is type I and when the diabetes is uncontrolled. Make an effort to document these points when present.

Your coder should add additional diagnosis codes to describe the ophthalmic manifestations of diabetes. Those include codes for diabetic blindness, cataract, glaucoma, macular edema, and "retinopathy." There are also separate codes for rubeosis iridis, ischemic optic neuropathy, and other manifestations of the disease.

Retinopathy is subdivided into background (specified as microaneurysms), non-proliferative, and proliferative. Diabetic macular edema can also be coded.

The testing services that are probably most commonly performed in patients with diabetic retinopathy are CPT 92235, Fluorescein angiography; CPT 92250, Fundus photography; and optical coherence tomography (OCT), which is appropriately coded as CPT 92135, Scanning computerized ophthalmic diagnostic imaging.

Medical necessity

For all tests, medical necessity must be demonstrated. Normal eyes (even when the contralateral eye demonstrates pathology) cannot be coded with a diagnosis code reflecting pathology. The test will generally be denied for normal eyes because medical necessity will not be apparent, lacking an appropriate diagnosis code for the test.

Interpretation and reporting is required for all three tests. Simply filing the study in the chart is inadequate. Ideally, the interpretation and report will appear separate from the office visit in the medical record. This is because the testing code is distinct from the office visit code, and separate documentation emphasizes the distinction.

Both fluorescein angiography and OCT are payable per eye. When both eyes demonstrate pathology, each eye is coded with the –RT or –LT modifier, respectively. For Medicare patients, the bilateral modifier –50 may be used.

Fundus photography is a bilateral code. That means payment has been based on both eyes being tested. Report bilateral cases with the base code, CPT 92250. Unilateral cases may be reported with –RT or –LT.

Medicare's National Correct Coding Initiative bundles fundus photography with OCT. Medicare's logic (often challenged) is that the two tests provide overlapping information. For commercial carriers, you may bill for both tests when performed on the same day, but in many cases one of the tests will be denied.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.